Project Grant R61AG090388
Award Date
1/15/25
Completion Date
12/31/26
Dollars Obligated
$614K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
This Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) provides $374,000.00 to develop and evaluate a novel chimeric antigen receptor (CAR) macrophage therapy targeting amyloid-beta aggregates for the treatment of Alzheimer's disease. The two-phase project aims to: 1) optimize the in vitro efficacy of the AB-targeting CAR macrophages and investigate their safety and central nervous system trafficking in vivo during the R61 phase; and 2) evaluate the short-...
This Project Grant award, funded by the National Institute on Aging (CFDA 93.866 Aging Research), provides $734,778 to the Regents of the University of Minnesota to develop and evaluate genetically engineered macrophages derived from human induced pluripotent stem cells (iPSC-iMF) for treating Alzheimer's disease and related dementias. The key objectives are to: 1) Design novel chimeric antigen receptor (CAR) constructs targeting pathogenic tau protein, and 2) Utilize genome editing to...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $810,596 to New York University School of Medicine to develop an "off-the-shelf" chimeric antigen receptor (CAR) macrophage therapy for Alzheimer's disease. The key products and services to be delivered under this R61/R33 grant include: Optimizing the transdifferentiation of human induced pluripotent stem cells (hiPSCs) into self-sustainable, CAR-expressing macrophage/microglia...
This $704,198 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) to the Trustees of Dartmouth College aims to develop chimeric antigen receptor (CAR) T regulatory cells (Tregs) targeted to amyloid-beta (Aβ) aggregates for the treatment of Alzheimer's disease (AD). The key objectives are to engineer CAR Tregs that can persist in the central nervous system (CNS) and rebalance cerebral immunity, promote Aβ clearance, and limit neuronal damage. The grant will...
This $728,370 Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of engineered T cell approaches for Alzheimer's disease. The primary awardee, The Washington University, will design and test "CARDINAL" (CAR Disease Interventions for Alzheimer's) T cells that are programmed to expand and persist at the site of Alzheimer's pathology. These T cells will be engineered to secrete neuroprotective payloads such as IL-4 and BDNF,...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $751,442 to the University of California, Los Angeles (UCLA) to develop and evaluate a brain-permeable CRISPR-based gene editing therapy for Alzheimer's disease (AD). The key products/services include: Optimizing a microfluidic synthetic exosome (SE) system to deliver CRISPR components that can edit the APOE4 gene, a major genetic risk factor for sporadic AD, to the less pathogenic APOE3...
The National Institute on Aging (NIA) awarded a $614,424 Project Grant (CFDA 93.866 - Aging Research) to the University of Washington to conduct research on Alzheimer's disease (AD) pathogenesis. The research aims to use novel explainable AI techniques and induced pluripotent stem cell (iPSC) models to better understand the role of microglia, the brain's immune cells, in the early stages of AD development. The project will integrate the AI approach with deep learning methods to identify subtle...
The Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $195,896.00 to The Washington University in St. Louis to develop a novel hybrid viral vector for CRISPR-based gene therapy. The project aims to create a chimeric adenovirus-adeno-associated virus (AdAAV) delivery system that can efficiently insert multiple transgenes into target cells. This approach is intended to enable treatment of complex, multigenic conditions like Alzheimer's disease,...
This Project Grant award from the National Institute on Aging's Aging Research federal grant program (CFDA 93.866) provides $871,419 to the University of Washington to conduct research on the role of microglia, the brain's immune cells, in the pathogenesis of Alzheimer's disease. The research aims to characterize molecular profiles and spatial organization of microglia across the adult age spectrum, both with and without Alzheimer's disease, through single-nucleus RNA sequencing of over 5,000...
This Project Grant award, valued at $10,847,672 and funded by the National Institute on Aging's Aging Research program (CFDA 93.866), supports research on the mechanisms underlying cerebral amyloid angiopathy (CAA) and its relationship to Alzheimer's disease pathology. The primary awardee, J. David Gladstone Institutes, will conduct comprehensive studies using human postmortem brain samples, single-cell genomics, and mouse models to elucidate how microglia regulate the balance between vascular...